陈 露,姜海燕

在全球范围内造成各种不良心血管事件发生的主要原因在于动脉粥样硬化的发生，根据有关研究表明，载脂蛋白（Apo）B是比低密度脂蛋白更准确的描述人体内血脂异常状况的生化指标，同时它对已经有冠脉狭窄并行冠脉支架植入术后患者预后的评估有明确价值。载脂蛋白A1是用来描述高密度脂蛋白颗粒数更加准确的治疗，并且不受降脂药物的影响。而载脂蛋白D不仅与胆固醇过度积累致动脉粥样硬化有关，还与神经系统疾病显著相关。载脂蛋白E明确与阿尔兹海默症明确相关，与冠状动脉的相关性仍在进一步研究中。本文就各类载脂蛋白在动脉粥样硬化中的基因及机制做如下综述。

动脉粥样硬化；载脂蛋白A；载脂蛋白B；载脂蛋白D；载脂蛋白E

[1] Chen L, Zhao Z W, Zeng P H, et al. Molecular mechanisms for ABCA1-mediated cholesterol efflux [J]. Cell Cycle, 2022, 21(11): 1121-39. [2] Huang J K, Lee H C. Emerging Evidence of Pathological Roles of Very-Low-Density Lipoprotein (VLDL) [J]. Int J Mol Sci, 2022, 23(8). [3] Glavinovic T, Thanassoulis G, de Graaf J, et al. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk [J]. J Am Heart Assoc, 2022, 11(20): e025858. [4] Mehta A, Shapiro M D. Apolipoproteins in vascular biology and atherosclerotic disease [J]. Nat Rev Cardiol, 2022, 19(3): 168-79. [5] Sniderman A D, Thanassoulis G, Glavinovic T, et al. Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review [J]. JAMA Cardiol, 2019, 4(12): 1287-95. [6] Tall A R, Thomas D G, Gonzalez-Cabodevilla A G, et al. Addressing dyslipidemic risk beyond LDL-cholesterol [J]. J Clin Invest, 2022, 132(1). [7] Warden B A, Duell P B. Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins [J]. J Cardiovasc Pharmacol, 2021, 78(2): e157-e74. [8] Ulloque-Badaracco J R, Al-Kassab-Córdova A, Hernandez-Bustamante E A, et al. Association of apolipoproteins and lipoprotein(a) with metabolic syndrome: a systematic review and meta-analysis [J]. Lipids Health Dis, 2023, 22(1): 98. [9] Borhani D W, Rogers D P, Engler J A, et al. Crystal structure of truncated human apolipoprotein A-I suggests a lipid-bound conformation [J]. Proc Natl Acad Sci U S A, 1997, 94(23): 12291-6. [10] Liu M, Mei X, Herscovitz H, et al. N-terminal mutation of apoA-I and interaction with ABCA1 reveal mechanisms of nascent HDL biogenesis [J]. J Lipid Res, 2019, 60(1): 44-57. [11] Bhale A S, Venkataraman K. Leveraging knowledge of HDLs major protein ApoA1: Structure, function, mutations, and potential therapeutics [J]. Biomed Pharmacother, 2022, 154: 113634. [12] Fyfe-Desmarais G, Desmarais F, Rassart É, et al. Apolipoprotein D in Oxidative Stress and Inflammation [J]. Antioxidants (Basel), 2023, 12(5). [13] Rassart E, Desmarais F, Najyb O, et al. Apolipoprotein D [J]. Gene, 2020, 756: 144874. [14] Wisniewski T, Drummond E. APOE-amyloid interaction: Therapeutic targets [J]. Neurobiol Dis, 2020, 138: 104784.

点击下载PDF